Jay Venkatesan - Feb 9, 2021 Form 4/A - Amendment Insider Report for Angion Biomedica Corp. (ELTX)

Role: President and Chief Executive Officer and Director, Director
Signature: /s/ Jennifer J. Rhodes, as attorney-in fact for Jay. R. Venkatesan
Stock symbol: ELTX
Transactions as of: Feb 9, 2021
Transactions value $: $4,595
Form type: 4/A - Amendment
Date filed: 5/27/2022, 04:20 PM
Date Of Original Report: Feb 11, 2021
Next filing: Dec 17, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELTX	Common Stock	Exercise of in-the-money or at-the-money derivative security	$2.55M	+396K	+32.97%	$6.43	1.6M	Feb 9, 2021	Direct
transaction	ELTX	Common Stock	Sale	-$2.55M	-159K	-10.43%	$16.00	1.37M	Feb 9, 2021	Direct	F1
transaction	ELTX	Common Stock	Conversion of derivative security	$3.03K	+262	+0.02%	$11.57	1.44M	Feb 9, 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELTX	Warrant to Purchase Common Stock	Exercise of in-the-money or at-the-money derivative security	$0	-396K	-100%	$0.00^*	0	Feb 9, 2021	Common Stock	396K	$6.43	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,329 shares of the Issuer's common stock for $6.43 a share. The Reporting Person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 159,177 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 237,152 shares of common stock.

Remarks:

President and Chief Executive Officer and Director